423735-93-7
423735-93-7
Chemical Structure
Parmodulin 2
Synonym(s): ML161
- CAS No.: 423735-93-7
- Formula:C17H17BrN2O2
- Molecular Weight:361.23
IUPAC Name: 2-bromo-N-(3-butyramidophenyl)benzamide
InChIKey: DFOVLSMXPWPCFH-UHFFFAOYSA-N
SMILES: O=C(NC1=CC=CC(NC(CCC)=O)=C1)C2=CC=CC=C2Br
Biological Activity: Parmodulin 2 (ML161) is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC50 of 0.26 μM[1]. Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Parmodulin 2 | 99.80% | Parmodulin 2 (ML161) is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC50 of 0.26 μM. Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.93
HY-128009ML161 analog 1 -
Similarity Score 0.66
HY-50934RTacedinaline (Standard) -
Similarity Score 0.66
HY-118352LB-205 -
Similarity Score 0.65
HY-124408Mepronil -
Similarity Score 0.65
HY-1269442-Aminobenzanilide -
Similarity Score 0.65
HY-100384NKL 22 -
Similarity Score 0.65
HY-108422RBenodanil (Standard) -
Similarity Score 0.64
HY-B1408Salicylanilide -
Similarity Score 0.64
HY-40310N-(4-Bromphenyl)-3-phenylpropanamid -
Explore the MedChemAI to find more analogs
References
- [1]. Gandhi DM, et al. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells. Bioorg Med Chem. 2018 May 15;26(9):2514-2529. [Content Brief]
- [2]. Susanna F Gunnink, et al. Allosteric inhibition of protease activated receptor 1: a new antiplatelet therapy.
